BiBBInstruments was born from a combination of Dr Charles Walther’s clinical work as a doctor taking tumor samples and his research as a PhD student in cancer diagnostics. The experience of taking biopsies every day together with research findings showing what type of biopsies provided the most information, resulted in a series of new biopsy instruments aimed at improving clinical cancer diagnostics. As a result, BiBBInstruments AB was founded in 2013 together with Lund University.
What have been the milestones so far in your company development?
Some of our major milestones since the founding of the company in 2013 have been: – Commercial launch of two unique products in our EndoDrill® Product Family, including EndoDrill® GI Upper for biopsy sampling of deep tumors in the upper GI tract (2017) and EndoDrill® Core Needle for sampling of tissue in breast, prostate, liver etc (2019). – Received several prestigious awards and grants such as SuperStartup of the Year in 2016 and grants from Vinnova, EU Horizon and Kamprad Family Office. – Built an extensive IP portfolio with pending and granted patents for our major markets. – Successfully listed BiBBInstruments at the Spotlight Stock Market in 2017. – Financed the whole startup, development and early commercial phases and just recently succeeded to attract a large long-term owner (Creades AB) – Published an impressive randomized clinical study for the first product EndoDrill® GI Upper (2016) and recently conducted a very promising pre-clinical trial for EndoDrill® Model X, our new generation of endoscopic biopsy instruments.
What are your most important markets, segments and customers?
BiBB is developing single-use biopsy instruments to improve diagnosis of the all common cancer types. Our product range is divided into endoscopic biopsy instruments (including products for endoscopic ultrasound) and percutaneous biopsy needles. We are targeting the global multi-billion market for biopsy instruments and our customers are public and private hospitals that offer biopsy investigation.
Where do you see the company five years from now?
Within five years BiBB has developed and commercialized a complete product range of revolutionary EndoDrill® biopsy instruments. Our products are at this time distributed worldwide by one of the major global medtech distributors.
What are your priorities within 2019/20?
We will continue our sales activities with our own sales force in Sweden and in some selected EU markets. However, our focus will be on the development of the EndoDrill® Model X which is a completely new innovation that could improve biopsy sampling for all endoscopic applications. During 2019-2020 we will conduct a multicenter trial in Sweden and begin commercialization (Generation 1). During this time period we also strive to have one or more EndoDrill® products approved in the USA by FDA (510(k).
Why should one consider adding your company into their portfolio?
– An already large and ever growing global multi-billion dollar market. – Exciting pipeline of unique biopsy instruments which help solve real clinical problems complimented with a scalable business model. – Already today, at a fairly early commercial stage (before we have developed a complete product portfolio), we see great interest from users and the industry.